BreezeBio
PrivateLast Round
Series B
Feb 25, 2026
Total Funding Raised
$153.55M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
BreezeBio operates in Healthcare & Life Sciences and is based in South San Francisco, California. Its latest recorded funding round was a Series B round in February 2026.
BreezeBio is a biotechnology company that develops precision genetic medicines for autoimmune diseases and oncology using its proprietary NanoGalaxy nanoparticle delivery platform.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting, Revenue Share
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
BreezeBio Comparables
Compare BreezeBio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Code Biotherapeutics | 88% | |
| ViaNautis Bio | 84% | |
| Hopewell Therapeutics | 82% |
For institutional investors. Book with your work email.
BreezeBio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Feb 25, 2026 | ||||
| Series B | Nov 20, 2024 | ||||
| Series A Extension | Jan 23, 2024 | ||||
| Grant | Dec 13, 2023 | ||||
| Series A | Sep 23, 2021 | ||||
Seed | Dec 11, 2018 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
BreezeBio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| SV Investment | Series B |
| DSC Investment | Series B |
| Top Harvest Capital | Series B |
| K2 Investment Partners | Series A Extension |
| IMM Investment | Series A, Series A Extension |
| KB Investment | Series A, Series A Extension |
| DAYLI Partners | Series A Extension, Series B, Series A |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 2, 2026
Focus on IND-enabling studies for genetic medicine delivery platform.
- Feb 25, 2026
$60M round led by DSC Investment and Yuanta Investment.
For institutional investors. Book with your work email.
BreezeBio Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about BreezeBio's valuation, stock price, and market status.
Is BreezeBio a public or private company?
BreezeBio is a private company.
What is the current stock price of BreezeBio?
BreezeBio is a private company, so its shares have no public market price. Caplight tracks BreezeBio's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is BreezeBio worth (valuation)?
Valuation information for BreezeBio is not publicly available.
Can I buy BreezeBio stock?
BreezeBio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was BreezeBio's last funding round?
BreezeBio's most recent funding round was Series B on February 25, 2026.
Who are the main investors in BreezeBio?
Key investors in BreezeBio include DSC Investment, DAYLI Partners, DCVC Bio, SK Inc., Company K Partners.
Will BreezeBio IPO soon?
No public IPO plans have been announced for BreezeBio.
How can I track BreezeBio secondary market activity?
Caplight tracks bids, offers, and trades in BreezeBio's shares on secondary markets.